<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176592</url>
  </required_header>
  <id_info>
    <org_study_id>0120020167</org_study_id>
    <secondary_id>0120020167</secondary_id>
    <nct_id>NCT00176592</nct_id>
  </id_info>
  <brief_title>Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI</brief_title>
  <acronym>BECOME</acronym>
  <official_title>Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first comparison of efficacy of Betaseron and Copaxone for treatment of relapsing&#xD;
      forms of MS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to perform a head to head comparison of Interferon beta and Copaxone for treatment&#xD;
      of patients with CIS and RR forms of MS using acute changes on MRI as primary outcome. The&#xD;
      study will be performed at the two clinical practice sites of the Multiple Sclerosis Center&#xD;
      at University of Medicine and Dentistry New Jersey-New Jersey Medical School, One of the two&#xD;
      FDA approved preparations of higher dose interferon beta (Betaseron) will be compared at&#xD;
      standard dose every other day (QOD) 250 ug subcutaneously(SQ) with Copaxone at 20mg SQ daily&#xD;
      (QD) in 70 to 80 patients. Although the current approved plan is to perform monthly MRIs for&#xD;
      1 year followed by another MRI at 2 years, the protocol has been changed to continue&#xD;
      performing monthly MRIs during the second year of the study for all patients who complete&#xD;
      their first year and up to January 31, 2006 when the study will end. The study uses brain&#xD;
      imaging with 3 Tesla MRI with triple dose Gadolinium for primary and secondary outcomes and&#xD;
      several clinical and cognitive measures for secondary outcomes. The sample size was estimated&#xD;
      to detect a 40-50% difference in the number of active MS lesions by MRI between the two arms&#xD;
      at 1 year follow up, consistent with the primary outcome measure. The primary outcome measure&#xD;
      is the number of &quot;combined-active&quot; lesions by monthly MRI at the conclusion of the study,&#xD;
      which includes contrast enhancing lesions and non-enhancing lesions on long Time repetition&#xD;
      (TR) scans that have appeared since the most recent examination. Several secondary MRI&#xD;
      outcome measures are studied in addition to the number of enhancing lesions and the number of&#xD;
      new lesions on long TR images. We will examine the number of patients who remain&#xD;
      &quot;combined-active disease-free&quot; for the duration of the study and the number of&#xD;
      &quot;combined-active disease-free&quot; scans. Apart from these traditional methods of analysis by a&#xD;
      reader who will be blinded to patient clinical status and therapy, objective volumetric&#xD;
      analysis will be carried out. Making use of both automated and manual techniques, we will&#xD;
      determine the overall burden of disease (the volume of lesions on long TR scans), the burden&#xD;
      of active disease (the volume of brain enhancement) and the burden of chronic disease (the&#xD;
      volume of lesions that are markedly hypointense on T1). Another MRI outcome measures will be&#xD;
      detection of diffusion anisotropy differences, MR spectroscopy, and magnetization transfer&#xD;
      ratio as summarized in Appendix 5. These new techniques have shown promise for detecting&#xD;
      disease that cannot be detected with conventional MRI (13, 37).&#xD;
&#xD;
      In addition to MRI, several clinical and cognitive outcome measures will be used for&#xD;
      secondary analysis. These include the number and severity of relapses measured by different&#xD;
      methods, and change in disability measured by the Expanded Disability Status Scale (EDSS),&#xD;
      the Neurological Rating Scale, and the Multiple Sclerosis Functional Composite (MSFC). The&#xD;
      cognitive measures will be the subject's neurocognitive function measured by standard&#xD;
      neurocognitive examination obtained by a licensed neuropsychologist and the Cognitive&#xD;
      Stability Index (CSI), a novel Internet-based test of cognitive function in addition to the&#xD;
      Paced Auditory Serial Addition Test (PASAT),which is a component of the MSFC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure is the Number of &quot;Combined Active Lesions&quot; (CAL) by Monthly MRI at the Conclusion of the Study.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Results are per patient mean number of lesions per scan. Results are per patient mean number of lesions per elapsed month. Contrasts types are: IFN 1b interferon beta 1b and GA glatiramer acetate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Enhancing Lesions.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The first part of the secondary outcome measure is the total number of enhancing lesions per patient per treatment arm.&#xD;
The second part of the secondary outcome is the total number of new enhancing lesions per patient per treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of MRI Disease Free Patients.</measure>
    <time_frame>1 year</time_frame>
    <description>The 1 year MRI results were used to determine the quantity of disease free patients per contrast type.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Betaseron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Betaseron 250 micrograms SQ every other day and Triple-Dose Gadolinium at each MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Copaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Copaxone 20 mg daily SQ and Triple-Dose Gadolinium at each MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaseron</intervention_name>
    <description>Betaseron 250 micrograms injected SQ every other day</description>
    <arm_group_label>Betaseron</arm_group_label>
    <other_name>Betaseron 250 mcg SQ every other day</other_name>
    <other_name>Intaferon beta 1 b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copaxone</intervention_name>
    <description>Copaxone 20 mg injected SQ every day (glatiramer acetate)</description>
    <arm_group_label>Copaxone</arm_group_label>
    <other_name>Copaxone 20 mg injected SQ every day (glatiramer acetate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients must meet all of the following criteria at the time of the baseline visit in order&#xD;
        to enter the trial:&#xD;
&#xD;
          -  Be Between 18 and 55 years of age, at baseline.&#xD;
&#xD;
          -  Be capable of informed consent in English prior to any study related&#xD;
             procedures.Spanish speaking patients who do not read English well can give written&#xD;
             informed consent if a relative or friend fluent in both English and Spanish has&#xD;
             translated the consent and any questions the patient may have.&#xD;
&#xD;
          -  Be available and willing to complete all study assessments.&#xD;
&#xD;
          -  Presently meet one of the two following forms of multiple sclerosis:&#xD;
&#xD;
               1. Relapsing-remitting ms plus evidence of recent disease activity as shown by the&#xD;
                  development of one or more clinical and/or MRI lesions during the 6 months prior&#xD;
                  to entry into the study.&#xD;
&#xD;
               2. A CIS consistent with central nervous system (CNS) demyelination confirmed on&#xD;
                  ophthalmologic or neurological examination with onset within 6 months prior to&#xD;
                  study entry. Also:a- evidence of dissemination in space, there should be two or&#xD;
                  more brain MRI lesions â‰¥ 3 mm in size at least one of which should be ovoid&#xD;
                  and/or periventricular in location; and b- As evidence of dissemination in time,&#xD;
                  if the CIS is acute (â‰¤1 month) there should be one or more non-enhancing lesion&#xD;
                  or if the CIS is not acute (older than 1 month) the MRI should show one or more&#xD;
                  enhancing lesions.&#xD;
&#xD;
                    -  At baseline, have an EDSS between 0-5.5.&#xD;
&#xD;
          -  Females of childbearing potential must agree to practice adequate contraception&#xD;
             methods. All females must have negative pregnancy test results at screening and a&#xD;
             negative urine pregnancy test at baseline.&#xD;
&#xD;
          -  Screening laboratory results that confirm adequate bone marrow, renal, and hepatic&#xD;
             function.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Patients were not permitted into the study if they met any of the following criteria:&#xD;
&#xD;
          -  Onset of a relapse between screening and Study Day 1.&#xD;
&#xD;
          -  Present evidence or history of any conditions that could affect the CNS or interfere&#xD;
             with the MRI results or any other evaluation in the study.&#xD;
&#xD;
          -  Possess any of the standard metallic devices or foreign bodies that are&#xD;
             contraindications for MRI.&#xD;
&#xD;
          -  Patient weight and or size unable to fit in the 3T MRI scanner.&#xD;
&#xD;
          -  Pregnancy, as denoted by a positive serum pregnancy test at screening visit or a&#xD;
             positive urine pregnancy test at the baseline visit. Subjects who are breast-feeding&#xD;
             are also excluded.&#xD;
&#xD;
          -  Have a known allergy or hypersensitivity to Gadolinium-chelates, human proteins&#xD;
             including albumin and interferons, or Glatiramer Acetate or Mannitol.&#xD;
&#xD;
          -  Uncontrolled, clinically significant heart diseases, such as dysrhythmias, angina, or&#xD;
             uncompensated congestive heart failure. History of or current unstable medical&#xD;
             conditions that could be deemed clinically significant.&#xD;
&#xD;
          -  Intolerance or any contraindication to acetaminophen, ibuprofen, or steroids.&#xD;
&#xD;
          -  Inability, in the opinion of the principal investigator or staff, to be compliant with&#xD;
             protocol requirements for the duration of the study.&#xD;
&#xD;
          -  Participation in any clinical trial within the past six months&#xD;
&#xD;
          -  History or present evidence of addictions.&#xD;
&#xD;
          -  Have active peptic ulcer disease.&#xD;
&#xD;
          -  Inability to have subcutaneous injections administered.&#xD;
&#xD;
          -  Medical, psychiatric or other conditions that compromise the patient's ability to&#xD;
             understand the study procedures.&#xD;
&#xD;
          -  Claustrophobia.&#xD;
&#xD;
          -  Uncontrolled head movements.&#xD;
&#xD;
          -  Treatment with any of the following in the indicated time frames: Any of the&#xD;
             Interferons for &gt; 6 monthsÂ· Glatiramer acetate (Copaxone) for &gt; 6 months.No prior use&#xD;
             allowed of Total lymphoid irradiation, Anti-lymphocyte monoclonal antibody&#xD;
             (e.g.(Campath-1H) .Mitoxantrone,cyclophosphamide, Azathioprine, intravenous&#xD;
             immunoglobulin (IVIG), cyclosporine within 6 months before the screening visitÂ·Any&#xD;
             investigational drug 21 days before screening visitÂ·Systemic corticosteroidsÂ·ACTH from&#xD;
             screening visit through Study Day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Cook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11.</citation>
    <PMID>19279320</PMID>
  </results_reference>
  <results_reference>
    <citation>Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry. 2009 Dec;80(12):1337-43. doi: 10.1136/jnnp.2008.171090. Epub 2009 Aug 16.</citation>
    <PMID>19687024</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>June 11, 2019</results_first_submitted>
  <results_first_submitted_qc>October 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2021</results_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Suhayl Dhib-Jalbut, MD</investigator_full_name>
    <investigator_title>Professor and Chair, Department of Neurology, NJMS &amp; RWJMS</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Brain</keyword>
  <keyword>Betaseron</keyword>
  <keyword>Copaxone</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Betaseron</title>
          <description>Betaseron 250 micrograms SQ every other day&#xD;
Betaseron: Betaseron 250 micrograms injected SQ every other day</description>
        </group>
        <group group_id="P2">
          <title>Copaxone</title>
          <description>20 mg daily SQ&#xD;
Copaxone: Copaxone 20 mg injected SQ every day (glatiramer acetate)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Followed for 1 Year</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Followed for 2 Years</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Betaseron</title>
          <description>Betaseron 250 micrograms SQ every other day&#xD;
Betaseron: Betaseron 250 micrograms injected SQ every other day</description>
        </group>
        <group group_id="B2">
          <title>Copaxone</title>
          <description>20 mg daily SQ&#xD;
Copaxone: Copaxone 20 mg injected SQ every day (glatiramer acetate)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B2" value="36" lower_limit="22" upper_limit="55"/>
                    <measurement group_id="B3" value="36" lower_limit="18" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure is the Number of &quot;Combined Active Lesions&quot; (CAL) by Monthly MRI at the Conclusion of the Study.</title>
        <description>Results are per patient mean number of lesions per scan. Results are per patient mean number of lesions per elapsed month. Contrasts types are: IFN 1b interferon beta 1b and GA glatiramer acetate.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Randomization was stratified by the presence or absence of enhancement. Analysis was intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Betaseron</title>
            <description>Betaseron 250 micrograms SQ every other day&#xD;
Betaseron: Betaseron 250 micrograms injected SQ every other day</description>
          </group>
          <group group_id="O2">
            <title>Copaxone</title>
            <description>20 mg daily SQ&#xD;
Copaxone: Copaxone 20 mg injected SQ every day (glatiramer acetate)</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Measure is the Number of &quot;Combined Active Lesions&quot; (CAL) by Monthly MRI at the Conclusion of the Study.</title>
          <description>Results are per patient mean number of lesions per scan. Results are per patient mean number of lesions per elapsed month. Contrasts types are: IFN 1b interferon beta 1b and GA glatiramer acetate.</description>
          <population>Randomization was stratified by the presence or absence of enhancement. Analysis was intention to treat.</population>
          <units>Average number of lesions per scan</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Combined Active Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Combined Active Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1688"/>
                <count group_id="O2" value="1053"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="2.76"/>
                    <measurement group_id="O2" value="0.58" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This includes p value for rank sum test treatment comparison. This includes p value for rank sum test treatment comparison of intention to treat study population.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This includes p value for rank sum test treatment comparison. This includes p value for rank sum test treatment comparison of intention to treat study population.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Enhancing Lesions.</title>
        <description>The first part of the secondary outcome measure is the total number of enhancing lesions per patient per treatment arm.&#xD;
The second part of the secondary outcome is the total number of new enhancing lesions per patient per treatment arm.</description>
        <time_frame>up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betaseron</title>
            <description>Betaseron 250 micrograms SQ every other day&#xD;
Betaseron: Betaseron 250 micrograms injected SQ every other day</description>
          </group>
          <group group_id="O2">
            <title>Copaxone</title>
            <description>20 mg daily SQ&#xD;
Copaxone: Copaxone 20 mg injected SQ every day (glatiramer acetate)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Enhancing Lesions.</title>
          <description>The first part of the secondary outcome measure is the total number of enhancing lesions per patient per treatment arm.&#xD;
The second part of the secondary outcome is the total number of new enhancing lesions per patient per treatment arm.</description>
          <units>New Enhancing Lesion</units>
          <param>Number</param>
          <units_analyzed>Enhancing Lesion</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Enhancing Lesion</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1531"/>
                <count group_id="O2" value="973"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="878"/>
                    <measurement group_id="O2" value="626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of MRI Disease Free Patients.</title>
        <description>The 1 year MRI results were used to determine the quantity of disease free patients per contrast type.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betaseron</title>
            <description>Betaseron 250 micrograms SQ every other day&#xD;
Betaseron: Betaseron 250 micrograms injected SQ every other day</description>
          </group>
          <group group_id="O2">
            <title>Copaxone</title>
            <description>20 mg daily SQ&#xD;
Copaxone: Copaxone 20 mg injected SQ every day (glatiramer acetate)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of MRI Disease Free Patients.</title>
          <description>The 1 year MRI results were used to determine the quantity of disease free patients per contrast type.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The number of relapse-free patients at the completion of the study.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free of combined active lesions, namely the combination of enhancing lesions plus new T2 lesions.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events in the form of symptoms were gathered over the duration of the study (24 months).</time_frame>
      <desc>Adverse events were recorded spontaneously and upon questioning by nurse at MRI for the hour of the MRI.&#xD;
Additional events were recorded at follow up visit within three months of MRI. Additional lab results were studied at follow up visit within three months of MRI.&#xD;
Finally, lab results and clinical adverse events were studied at three interim analyses by data monitoring committee.</desc>
      <group_list>
        <group group_id="E1">
          <title>Betaseron</title>
          <description>Betaseron 250 micrograms SQ every other day&#xD;
Betaseron: Betaseron 250 micrograms injected SQ every other day</description>
        </group>
        <group group_id="E2">
          <title>Copaxone</title>
          <description>20 mg daily SQ&#xD;
Copaxone: Copaxone 20 mg injected SQ every day (glatiramer acetate)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Venous Thromboembolism</sub_title>
                <description>Pain behind right knee while walking and standing. Deep vein thrombosis and pulmonary embolism. Treated at hospital.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of Hearing</sub_title>
                <description>Loss of hearing in left ear. Viral etiology. Treated by ENT.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Balance Impairment</sub_title>
                <description>Patient experienced balance impairment for about 1 week; MRI showed multiple enhancing lesions.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Patient experienced vomiting up all food and liquids; vertigo; severe gastroenteritis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Gastritis; nausea and vomiting; brainstem MS relapse.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain in right shoulder and leg. No foot sensation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pain near IV Site</sub_title>
                <description>During MRI, pain near IV site (right forearm). Extravasated contrast/IV fluid.Swelling, decreased skin temp, increased paresthesias and skin turned black near site.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelitis</sub_title>
                <description>Severe myelitis, bilateral leg weakness, dysesthesias, impaired balance.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <description>One Patient had normal pregnancy and delivery. Discontinued drug and no longer participated in the study. Other two patients terminated pregnancy.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Malignant Nodule in Lung</sub_title>
                <description>Patient had a chest x-ray that showed nodule which was malignant. Patient had surgery to remove 1 lobe, right lung.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <description>Patient found to have three aneurysms. Two were clipped and one wrapped, Mild left sided stroke suffered.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain/Burning at Injection Site</sub_title>
                <description>Complained of pain and/or burning at site of injection.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache/Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Back pain, pain in upper arm/shoulder above IN, neck/shoulder pain, shoulder pain, and pain in left arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stuart Cook, MD</name_or_title>
      <organization>Rutgers New Jersey Medical School</organization>
      <phone>973-972-2550</phone>
      <email>cooksd@njms.rutgers.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

